Literature DB >> 12069

Effect of metiamide on basal and stimulated serum cholecystokinin levels in duodenal ulcer patients.

R W Spence, L R Celestin, R F Harvey.   

Abstract

Serum cholecystokinin (CCK) levels were measured in 10 patients with chronic duodenal ulcers, fasting and at intervals after two standard tests meals (300 ml of 40 mmol/1 phenylalanine solution), one given before and one during H2-receptor blockade with metiamide (200 mg four times a day). Fasting serum CCK levels were lower in all patients during treatment with metiamide (the mean level falling from 306-0 +/- 102-0 (SEM) to 82-1 +/- 23-6 pg/ml after treatment (p less than 0-01)). In contrast, peak serum CCK levels after the meal were not significantly different (7400 +/- 1141 pg/ml before treatment and 7569 +/- 1293 pg/ml on metiamide). We conclude that in duodenal ulcer patients CCK secretion under basal condtions may be in part dependent on stimulation of the small intestinal mucosa by gastric acid, but that, after an amino acid meal, gastric acid secretion is less important in determining the amount of CCK released.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 12069      PMCID: PMC1411204          DOI: 10.1136/gut.17.11.920

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Proceedings: Response to jejunal acidification in patients with duodenal ulcer and normal subjects.

Authors:  B Thjodleifsson; K G Wormsley
Journal:  Gut       Date:  1975-10       Impact factor: 23.059

2.  Release of cholecystokinin by acid (38562).

Authors:  G O Barbezat; M I Grossman
Journal:  Proc Soc Exp Biol Med       Date:  1975-02

3.  Physiological determination of release of secretin and pancreozymin from intestine of dogs with transplanted pancreas.

Authors:  C C WANG; M I GROSSMAN
Journal:  Am J Physiol       Date:  1951-02

4.  Proceedings: Studies on the nature of cholecystokininpancreozymin in small-intestinal mucosal extracts.

Authors:  R F Harvey; L Dowsett; A E Read
Journal:  Gut       Date:  1974-10       Impact factor: 23.059

5.  Inhibition of nocturnal acid secretion in duodenal ulcer by one oral dose of metiamide.

Authors:  G J Milton-Thompson; J G Williams; D J Jenkins; J J Misiewicz
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

6.  A radioimmunoassay for cholecystokinin-pancreozymin.

Authors:  R F Harvey; L Dowsett; M Hartog; A E Read
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

7.  Metiamide--an orally active histamine H2-receptor antagonist.

Authors:  J W Black; W A Duncan; J C Emmett; C R Ganellin; T Hesselbo; M E Parsons; J H Wyllie
Journal:  Agents Actions       Date:  1973-10

8.  Metiamide, an H2-receptor blocker, as inhibitor of basal and meal-stimulated gastric acid secretion in patients with duodenal ulcer.

Authors:  M Mainardi; V Maxwell; R A Sturdevant; J I Isenberg
Journal:  N Engl J Med       Date:  1974-08-22       Impact factor: 91.245

9.  Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer.

Authors:  R M Henn; J I Isenberg; V Maxwell; R A Sturdevant
Journal:  N Engl J Med       Date:  1975-08-21       Impact factor: 91.245

10.  Cholecystokinin metabolism in man and dogs.

Authors:  J C Thompson; H R Fender; N I Ramus; H V Villar; P L Rayford
Journal:  Ann Surg       Date:  1975-10       Impact factor: 12.969

View more
  2 in total

1.  Cholecystokinin-like activity in the duodenal mucosa of duodenal ulcer patients.

Authors:  S Kataoka
Journal:  Gut       Date:  1982-05       Impact factor: 23.059

2.  Immunological blocking of exogenous and endogenous secretin in the dog.

Authors:  L Kayasseh; K Gyr; J B Baumann; J Girard
Journal:  Experientia       Date:  1979-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.